Bevacizumab 生物类似药, 人 VEGF 单克隆抗体-Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody代理/参数/厂家-二抗-开云·官方站线上登录平台入口

欢迎您访问武汉开云·官方站线上登录平台入口_开云(中国) 官方网站！

站点地图服务热线：400-6800-868

PRODUCT CENTER

二抗

开云·官方站线上登录平台入口_开云(中国)

当前位置：开云·官方站线上登录平台入口 > 开云·官方站线上登录平台入口_开云(中国) > 免疫学产品 > 二抗

背景资料: Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.nnVascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.

保存建议: Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.

其他: ProMab 生物技术公司通过整合生物信息学、分子生物学、蛋白质表达、纯化技术、基因克隆、微生物学和免疫学，利用新型高通量技术开发重组蛋白、抗体和工程细胞系并将其商业化。专注于免疫治疗领域，特别是 CAR-T/NK 细胞技术。ProMab 还开发了一种新型的 mRNA 脂质纳米颗粒（mRNA-LNP）平台，用于即用型试剂和定制研究服务，以推进现有产品并扩展到更多的研究领域。